New Zealand-To-Australia Firm Innate Launches IPO To Fund MS Trials
This article was originally published in PharmAsia News
Executive Summary
Australia's Innate Immunotherapeutics, formerly headquartered in New Zealand, has launched a U.S.$11 million initial public offering to finance a Phase IIb trial of its MIS416 drug for treating secondary progressive multiple sclerosis.